002773 康弘药业
已收盘 05-17 15:00:00
资讯
新帖
简况
康弘药业(002773)5月16日主力资金净卖出4518.99万元
证券之星 · 05-17 09:22
康弘药业(002773)5月16日主力资金净卖出4518.99万元
康弘药业(002773)5月15日主力资金净卖出6326.59万元
证券之星 · 05-16
康弘药业(002773)5月15日主力资金净卖出6326.59万元
康弘药业:我司立他司特滴眼液正在CDE审评审批,目前审评状态正常
证券之星 · 05-14
康弘药业:我司立他司特滴眼液正在CDE审评审批,目前审评状态正常
康弘药业:公司管理层在日常经营管理中,严控信用风险,勤勉尽责
证券之星 · 05-09
康弘药业:公司管理层在日常经营管理中,严控信用风险,勤勉尽责
康弘药业(002773)5月7日主力资金净买入3552.57万元
证券之星 · 05-08
康弘药业(002773)5月7日主力资金净买入3552.57万元
康弘药业:截至2024年4月30日,公司股东户数为39,839户
证券之星 · 05-06
康弘药业:截至2024年4月30日,公司股东户数为39,839户
康弘药业(002773.SZ):KH658眼用注射液在美临床试验获美国食品药品管理局批准
智通财经网 · 04-29
康弘药业(002773.SZ):KH658眼用注射液在美临床试验获美国食品药品管理局批准
康弘药业(002773.SZ):KH658眼用注射液临床试验获批
智通财经 · 04-29
康弘药业(002773.SZ):KH658眼用注射液临床试验获批
非酒精性脂肪性肝炎(NASH)概念盘中拉升,康弘药业涨3.92%
自选股智能写手 · 04-26
非酒精性脂肪性肝炎(NASH)概念盘中拉升,康弘药业涨3.92%
4月25日康弘药业连续2日创60日新高,万家中证1000指数增强A基金重仓该股
证券之星 · 04-25
4月25日康弘药业连续2日创60日新高,万家中证1000指数增强A基金重仓该股
4月25日康弘药业涨停分析:眼科,合成生物,创新药概念热股
证券之星 · 04-25
4月25日康弘药业涨停分析:眼科,合成生物,创新药概念热股
异动快报:康弘药业(002773)4月25日10点24分触及涨停板
证券之星 · 04-25
异动快报:康弘药业(002773)4月25日10点24分触及涨停板
图解康弘药业一季报:第一季度单季净利润同比增33.72%
证券之星 · 04-25
图解康弘药业一季报:第一季度单季净利润同比增33.72%
康弘药业(002773.SZ)发布一季度业绩 净利润3.74亿元 同比增长33.72%
智通财经 · 04-24
康弘药业(002773.SZ)发布一季度业绩 净利润3.74亿元 同比增长33.72%
康弘药业最新公告:一季度净利润3.71亿元 同比增长33.72%
证券之星 · 04-24
康弘药业最新公告:一季度净利润3.71亿元 同比增长33.72%
康弘药业(002773.SZ)发布2023年度业绩 净利润10.45亿元 同比增长16.52%
智通财经网 · 04-24
康弘药业(002773.SZ)发布2023年度业绩 净利润10.45亿元 同比增长16.52%
康弘药业:公司中药材种植品种没有白术
证券之星 · 04-23
康弘药业:公司中药材种植品种没有白术
康弘药业:截至2024年4月19日,公司股东户数为38,430户
证券之星 · 04-22
康弘药业:截至2024年4月19日,公司股东户数为38,430户
暂无数据
公司概况
公司名称:
成都康弘药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2015-06-26
主营业务:
成都康弘药业集团股份有限公司主营业务为药品(包括生物制品、中成药、化学药)和医疗器械(主要是眼科医疗器械)的研发、生产与销售。公司目前上市产品主要为康柏西普眼用注射液、舒肝解郁胶囊、松龄血脉康胶囊、渴络欣胶囊、胆舒胶囊、一清胶囊、盐酸文拉法辛缓释片、阿立哌唑口崩片、阿立哌唑口服溶液、枸橼酸莫沙必利片、枸橼酸莫沙必利分散片、右佐匹克隆片等药品和医疗器械。
发行价格:
13.62
{"stockData":{"symbol":"002773","market":"SZ","secType":"STK","nameCN":"康弘药业","latestPrice":22.71,"timestamp":1715929437000,"preClose":22.56,"halted":0,"volume":8978113,"delay":0,"floatShares":685000000,"shares":919000000,"eps":1.2388,"marketStatus":"已收盘","marketStatusCode":5,"change":0.15,"latestTime":"05-17 15:00:00","open":22.69,"high":22.9,"low":22.37,"amount":203000000,"amplitude":0.0235,"askPrice":22.72,"askSize":18,"bidPrice":22.71,"bidSize":207,"shortable":0,"etf":0,"ttmEps":1.2388,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716168600000},"adr":0,"adjPreClose":22.56,"symbolType":"stock","openAndCloseTimeList":[[1715909400000,1715916600000],[1715922000000,1715929200000]],"highLimit":24.82,"lowLimit":20.3,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":919463954,"pbRate":2.54,"roa":"--","roe":"4.67%","epsLYR":1.14,"committee":-0.388213,"marketValue":20881000000,"floatMarketCap":15557000000,"peRate":18.332256,"changeRate":0.0066,"turnoverRate":0.0131,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-05-20。"},"requestUrl":"/m/hq/s/002773/tweets","defaultTab":"tweets","newsList":[{"id":"2436793750","title":"康弘药业(002773)5月16日主力资金净卖出4518.99万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2436793750","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2436793750?lang=zh_cn&edition=full","pubTime":"2024-05-17 09:22","pubTimestamp":1715908960,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月16日收盘,康弘药业报收于22.56元,下跌1.57%,换手率2.11%,成交量14.47万手,成交额3.29亿元。近5日资金流向一览见下表:康弘药业融资融券信息显示,融资方面,当日融资买入2275.39万元,融资偿还4361.87万元,融资净偿还2086.47万元。康弘药业主营业务:药品和医疗器械的研发、生产与销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700015556.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435561875","title":"康弘药业(002773)5月15日主力资金净卖出6326.59万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435561875","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435561875?lang=zh_cn&edition=full","pubTime":"2024-05-16 09:19","pubTimestamp":1715822346,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月15日收盘,康弘药业报收于22.92元,下跌3.33%,换手率2.09%,成交量14.3万手,成交额3.32亿元。近5日资金流向一览见下表:康弘药业融资融券信息显示,融资方面,当日融资买入3145.72万元,融资偿还2574.62万元,融资净买入571.1万元。康弘药业主营业务:药品和医疗器械的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051600010137.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435939955","title":"康弘药业:我司立他司特滴眼液正在CDE审评审批,目前审评状态正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2435939955","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435939955?lang=zh_cn&edition=full","pubTime":"2024-05-14 18:02","pubTimestamp":1715680948,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)05月14日在投资者关系平台上答复投资者关心的问题。投资者:请问立他司特滴眼液在CDE中哪个阶段了?还有多久能上市?CDE评审都有几个阶段?康弘药业董秘:尊敬的投资者,您好!我司立他司特滴眼液正在CDE审评审批,目前审评状态正常。CDE对该类事项的审评流程,您可关注现行版《药品注册管理办法》相关规定。感谢您的关注与支持!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051400027230.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434064495","title":"康弘药业:公司管理层在日常经营管理中,严控信用风险,勤勉尽责","url":"https://stock-news.laohu8.com/highlight/detail?id=2434064495","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434064495?lang=zh_cn&edition=full","pubTime":"2024-05-09 18:02","pubTimestamp":1715248945,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业05月09日在投资者关系平台上答复投资者关心的问题。年报披露的其他应收款坏账准备已根据会计政策足额计提。公司将持续加强经营管理和内控建设,努力提升公司经营业绩。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050900032801.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433636237","title":"康弘药业(002773)5月7日主力资金净买入3552.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433636237","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433636237?lang=zh_cn&edition=full","pubTime":"2024-05-08 09:14","pubTimestamp":1715130851,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月7日收盘,康弘药业报收于23.88元,上涨4.92%,换手率3.45%,成交量23.62万手,成交额5.51亿元。近5日资金流向一览见下表:康弘药业融资融券信息显示,融资方面,当日融资买入5242.03万元,融资偿还3680.06万元,融资净买入1561.98万元,连续3日净买入累计5482.33万元。康弘药业主营业务:药品和医疗器械的研发、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800013883.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433864426","title":"康弘药业:截至2024年4月30日,公司股东户数为39,839户","url":"https://stock-news.laohu8.com/highlight/detail?id=2433864426","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433864426?lang=zh_cn&edition=full","pubTime":"2024-05-06 19:02","pubTimestamp":1714993328,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)05月06日在投资者关系平台上答复投资者关心的问题。投资者:尊敬的董秘,您好!请问公司最新的股东户数是多少?谢谢!康弘药业董秘:尊敬的投资者,您好!截至2024年4月30日,公司股东户数为39,839户。感谢您的关注与支持!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600021508.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431010617","title":"康弘药业(002773.SZ):KH658眼用注射液在美临床试验获美国食品药品管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2431010617","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2431010617?lang=zh_cn&edition=full","pubTime":"2024-04-29 08:10","pubTimestamp":1714349456,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业 发布公告,公司子公司成都弘基生物科技有限公司于美国时间2024年4月26日收到美国食品药品管理局准许KH658眼用注射液在美国开展临床试验的邮件。据悉,KH658眼用注射液是弘基生物第二款同时获批进入中国和美国临床试验的产品,以具有自主知识产权、基于细胞特异性受体设计的新型腺相关病毒作为递送载体,具有给药方式简便、安全、转导细胞效率高的特点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1113829.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431010828","title":"康弘药业(002773.SZ):KH658眼用注射液临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2431010828","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431010828?lang=zh_cn&edition=full","pubTime":"2024-04-29 08:05","pubTimestamp":1714349120,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)发布公告,2024年4月28日,公司子公司成都弘基生物科技有限公司申报的KH658眼用注射液获得中国药品监督管理局药物临床试验批准通知书,同意开展I/II期临床试验。据悉,KH658眼用注射液是弘基生物第二款同时获批进入中国和美国临床试验的产品,以具有自主知识产权、基于细胞特异性受体设计的新型腺相关病毒作为递送载体,具有给药方式简便、安全、转导细胞效率高的特点。本品通过在人体内持续表达抗VEGF蛋白,从而抑制新生血管病变的生长,减缓疾病的进展,有望以单次给药实现患者长期获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1113827.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430219525","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升,康弘药业涨3.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430219525","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430219525?lang=zh_cn&edition=full","pubTime":"2024-04-26 13:25","pubTimestamp":1714109121,"startTime":"0","endTime":"0","summary":"04月26日,非酒精性脂肪性肝炎(NASH)概念盘中拉升,截至13点25分,非酒精性脂肪性肝炎(NASH)概念整体指数上涨2.02%,报1067.430点。从个股上来看,该概念的成分股中,康弘药业涨3.92%,通化东宝、福瑞股份、天士力涨幅居前。从资金上来看,截止发稿,非酒精性脂肪性肝炎(NASH)概念主力净流入为660.84万,其中通化东宝受到资金热捧,主力净流入4556.22万;拉长时间线来看,该板块近20日主力资金净流入-4.25亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261325217923bbc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261325217923bbc2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430142744","title":"4月25日康弘药业连续2日创60日新高,万家中证1000指数增强A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430142744","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430142744?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:16","pubTimestamp":1714032986,"startTime":"0","endTime":"0","summary":"证券之星消息,4月25日康弘药业涨10.00%连续2日创60日新高,收盘报20.13元,换手率4.51%,成交量30.9万手,成交额6.16亿元。重仓康弘药业的前十大公募基金请见下表:根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共12家,其中持有数量最多的公募基金为万家中证1000指数增强A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500031980.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430636421","title":"4月25日康弘药业涨停分析:眼科,合成生物,创新药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430636421","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430636421?lang=zh_cn&edition=full","pubTime":"2024-04-25 15:28","pubTimestamp":1714030100,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业涨停收盘,收盘价20.13元。该股于9点42分涨停,5次打开涨停,截止收盘封单资金为3337.67万元,占其流通市值0.24%。4月25日的资金流向数据方面,主力资金净流入3968.23万元,占总成交额6.44%,游资资金净流出2841.33万元,占总成交额4.61%,散户资金净流出1126.9万元,占总成交额1.83%。近5日资金流向一览见下表:该股为眼科,合成生物,创新药概念热股,当日眼科概念上涨2.17%,合成生物概念上涨1.9%,创新药概念上涨1.85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500026139.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430410823","title":"异动快报:康弘药业(002773)4月25日10点24分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2430410823","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430410823?lang=zh_cn&edition=full","pubTime":"2024-04-25 10:25","pubTimestamp":1714011920,"startTime":"0","endTime":"0","summary":"证券之星4月25日盘中消息,10点24分康弘药业触及涨停板。目前价格20.13,上涨10.0%。其所属行业化学制药目前上涨。领涨股为常山药业。该股为眼科,阿尔茨海默病,合成生物概念热股,当日眼科概念上涨2.04%,阿尔茨海默病概念上涨1.65%,合成生物概念上涨1.45%。4月24日的资金流向数据方面,主力资金净流入1476.97万元,占总成交额8.89%,游资资金净流出205.75万元,占总成交额1.24%,散户资金净流出1271.22万元,占总成交额7.66%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500021726.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430619414","title":"图解康弘药业一季报:第一季度单季净利润同比增33.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430619414","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430619414?lang=zh_cn&edition=full","pubTime":"2024-04-25 01:39","pubTimestamp":1713980390,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业2024年一季报显示,公司主营收入10.93亿元,同比上升23.5%;归母净利润3.74亿元,同比上升33.72%;扣非净利润3.63亿元,同比上升36.18%;负债率7.36%,投资收益-5.32万元,财务费用-1629.9万元,毛利率89.49%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500002346.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429432312","title":"康弘药业(002773.SZ)发布一季度业绩 净利润3.74亿元 同比增长33.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429432312","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429432312?lang=zh_cn&edition=full","pubTime":"2024-04-24 19:42","pubTimestamp":1713958939,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)披露2024年第一季度报告,该公司报告期实现营业收入10.93亿元,同比增长23.50%。归属于上市公司股东的净利润3.74亿元,同比增长33.72%。归属于上市公司股东的扣除非经常性损益的净利润3.63亿元,同比增长36.18%。基本每股收益为0.41元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108946.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429072434","title":"康弘药业最新公告:一季度净利润3.71亿元 同比增长33.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429072434","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429072434?lang=zh_cn&edition=full","pubTime":"2024-04-24 19:39","pubTimestamp":1713958785,"startTime":"0","endTime":"0","summary":"康弘药业公告,一季度实现营业收入10.93亿元,同比增长23.50%;净利润3.71亿元,同比增长33.72%;基本每股收益0.41元。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400041121.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429843428","title":"康弘药业(002773.SZ)发布2023年度业绩 净利润10.45亿元 同比增长16.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429843428","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2429843428?lang=zh_cn&edition=full","pubTime":"2024-04-24 19:34","pubTimestamp":1713958487,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)披露2023年年度报告,该公司报告期实现营业收入39.57亿元,同比增长16.77%。归属于上市公司股东的净利润10.45亿元,同比增长16.52%。归属于上市公司股东的扣除非经常性损益的净利润10.14亿元,同比增长22.85%。基本每股收益为1.14元/股。拟每10股派发现金红利3.80元(含税)。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108923.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429863198","title":"康弘药业:公司中药材种植品种没有白术","url":"https://stock-news.laohu8.com/highlight/detail?id=2429863198","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429863198?lang=zh_cn&edition=full","pubTime":"2024-04-23 19:01","pubTimestamp":1713870109,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业04月23日在投资者关系平台上答复投资者关心的问题。公司中药材种植品种没有白术。四川康弘中药材种植有限公司在多个地区建立了中药材种植基地,种植品种包括贯叶金丝桃、刺五加、淫羊藿、葛根,种植面积近4000亩,更多信息敬请关注公司的相关公告。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300036626.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429945468","title":"康弘药业:截至2024年4月19日,公司股东户数为38,430户","url":"https://stock-news.laohu8.com/highlight/detail?id=2429945468","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429945468?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:04","pubTimestamp":1713780248,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)04月22日在投资者关系平台上答复投资者关心的问题。投资者:请问公司截至2024年4月20日股东户数是多少?谢谢。康弘药业董秘:尊敬的投资者,您好!截至2024年4月19日,公司股东户数为38,430户。感谢您的关注与支持!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200021539.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2015-06-26","address":"四川省成都市金牛区蜀西路108号","stockEarnings":[{"period":"1week","weight":-0.0402},{"period":"1month","weight":0.3104},{"period":"3month","weight":0.3705},{"period":"6month","weight":0.2694},{"period":"1year","weight":0.3208},{"period":"ytd","weight":0.2316}],"companyName":"成都康弘药业集团股份有限公司","boardCode":"AI0027","perCapita":"17588股","boardName":"医药制造业","registeredCapital":"91946万元","compareEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.1005},{"period":"6month","weight":0.0326},{"period":"1year","weight":-0.0435},{"period":"ytd","weight":0.0602}],"survey":" 成都康弘药业集团股份有限公司主营业务为药品(包括生物制品、中成药、化学药)和医疗器械(主要是眼科医疗器械)的研发、生产与销售。公司目前上市产品主要为康柏西普眼用注射液、舒肝解郁胶囊、松龄血脉康胶囊、渴络欣胶囊、胆舒胶囊、一清胶囊、盐酸文拉法辛缓释片、阿立哌唑口崩片、阿立哌唑口服溶液、枸橼酸莫沙必利片、枸橼酸莫沙必利分散片、右佐匹克隆片等药品和医疗器械。","serverTime":1716091151872,"listedPrice":13.62,"stockholders":"38947人(较上一季度减少2.24%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康弘药业,002773,康弘药业股票,康弘药业股票老虎,康弘药业股票老虎国际,康弘药业行情,康弘药业股票行情,康弘药业股价,康弘药业股市,康弘药业股票价格,康弘药业股票交易,康弘药业股票购买,康弘药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}